澳股详情

本页面由Tiger Trade Technology Pte. Ltd.提供服务

ACDC Metals Ltd

0.056

0.000

成交量：31.21万

成交额：1.75万

市值：419.61万

市盈率：-5.94

高：0.056

开：0.056

低：0.056

收：0.056

52周最高：0.160

52周最低：0.036

股本：7,493.08万

流通股本：4,028.75万

量比：4.34

换手率：0.77%

股息：- -

股息率：- -

每股收益(TTM):-0.009

每股收益(LYR):-0.009

净资产收益率：-6.71%

总资产收益率：-2.92%

市净率：0.41

市盈率(LYR):-5.94

数据加载中...

总览公司新闻资讯公告

Kelun-Biotech Presents Positive Results of Phase 3 Clinical Study OptiTROP-Breast02 for Sacituzumab Tirumotecan in Advanced HR+/HER2- Breast Cancer at 2025 ESMO

先声药业(02096.HK)：SIM0609(CDH17抗体偶联药物)获国家药品监督管理局签发药物临床试验批准通知书

招银国际：首次覆盖维立志博-B(09887.HK)予“买入”评级目标价63.5港元

阿斯利康第二款ADC药物在国内获批用于乳腺癌

阿斯利康宣布注射用德达博妥单抗（达卓优）正式在国内获批用于治疗既往接受过内分泌治疗且在晚期疾病阶段接受过至少一线化疗的不

研报掘金｜中金：上调药明合联目标价至75港元中期业绩胜预期且订单增长强劲

德琪医药-B(06996.HK)：ATG-022就治疗胃癌/胃食管结合部腺癌获授予突破性治疗药物认定

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hans/stock/ADC.AU/news"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"ADC.AU","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:true,,method:\"POST\",data:#items:@#symbol:\"ADC.AU\",,,,,undefined,":{"symbol":"ADC.AU","market":"AU","secType":"STK","nameCN":"ACDC Metals Ltd","latestPrice":0.056,"timestamp":1771909920000,"preClose":0.056,"halted":0,"volume":312050,"delay":0,"changeRate":0,"nameEN":"ACDC Metals Ltd","floatShares":40287509,"shares":74930755,"eps":-0.00943,"marketStatus":"未开盘","change":0,"latestTime":"02-24 16:12:00 AEDT","open":0.056,"high":0.056,"low":0.056,"amount":17475,"amplitude":0,"askPrice":0.062,"askSize":779,"bidPrice":0.056,"bidSize":187950,"shortable":3,"etf":0,"ttmEps":-0.00943,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":0,"beginTime":1771974000000},"marketStatusCode":0,"adr":0,"listingDate":1673787600000,"exchange":"ASX","adjPreClose":0.056,"openAndCloseTimeList":[[1771887600000,1771909200000]],"volumeRatio":4.338511,"lotSize":1,"tradeCurrency":"AUD"},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:true,,method:\"POST\",data:#items:@#symbol:\"ADC.AU\",,,,,undefined,":{"symbol":"ADC.AU","floatShares":40287509,"roa":"-2.92%","roe":"-6.71%","lyrEps":-0.00943,"volumeRatio":4.338511,"shares":74930755,"dividePrice":0,"high":0.056,"amplitude":0,"preClose":0.056,"low":0.056,"week52Low":0.036,"pbRate":"0.41","psRate":"12.18","week52High":0.16,"institutionHeld":0,"latestPrice":0.056,"committee":0.991745,"eps":-0.00943,"divideRate":0,"volume":312050,"delay":0,"ttmEps":-0.00943,"open":0.056,"prevYearClose":0.065,"prevWeekClose":0.057,"prevMonthClose":0.049,"prevQuarterClose":0.065,"fiveDayClose":0.057,"twentyDayClose":0.058,"sixtyDayClose":0.067},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/ADC.AU\",params:#limit:5,,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"ADC.AU\",market:\"AU\",,,undefined,":[],"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"ADC.AU\",pageSize:20,pageCount:1,lang_content:\"cn\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2576048378","title":"Kelun-Biotech Presents Positive Results of Phase 3 Clinical Study OptiTROP-Breast02 for Sacituzumab Tirumotecan in Advanced HR+/HER2- Breast Cancer at 2025 ESMO","url":"https://stock-news.laohu8.com/highlight/detail?id=2576048378","media":"prnewswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2576048378?lang=zh_cn&edition=fundamental","pubTime":"2025-10-18 22:46","pubTimestamp":1760798760,"startTime":"0","endTime":"0","summary":"CHENGDU, China, Oct. 18, 2025 /PRNewswire/ -- Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.  announced that at the 2025 European Society for Medical Oncology  Congress held in Berlin, Germany, results from a Phase 3 OptiTROP-Breast02 study of the Company's trophoblast cell-surface antigen 2 -directed antibody-drug conjugate sacituzumab tirumotecan (佳泰莱) in previously treated locally advanced or metastatic hormone receptor-positive (HR+) and human epidermal growth factor receptor 2 -negative  breast cancer  was presented as an oral report by Professor Man Li from the Second Affiliated Hospital of Dalian Medical University . Previously, the new indication applications for sac-TMT for this indication was accepted by the National Medical Products Administration  and was included in the priority review and approval process.","market":"fut","thumbnail":"https://mma.prnewswire.com/media/2799758/image_1.jpg?w=300","type":0,"news_type":0,"thumbnails":["https://mma.prnewswire.com/media/2799758/image_1.jpg?w=300"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.prnewswire.com/apac/news-releases/kelun-biotech-presents-positive-results-of-phase-3-clinical-study-optitrop-breast02-for-sacituzumab-tirumotecan-in-advanced-hrher2--breast-cancer-at-2025-esmo-302588212.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK7095","HR","BK4203","BC","ADC.AU","BK4190","BK4231","BK4225","BK4080","ADC"],"gpt_icon":0},{"id":"2565899846","title":"先声药业(02096.HK)：SIM0609(CDH17抗体偶联药物)获国家药品监督管理局签发药物临床试验批准通知书","url":"https://stock-news.laohu8.com/highlight/detail?id=2565899846","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2565899846?lang=zh_cn&edition=fundamental","pubTime":"2025-09-08 20:12","pubTimestamp":1757333548,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=ganggu","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["BK7095","BK4231","BK1583","ADC.AU","BK4080","ADC","BK1191","02096"],"gpt_icon":0},{"id":"2564325557","title":"招银国际：首次覆盖维立志博-B(09887.HK)予“买入”评级 目标价63.5港元","url":"https://stock-news.laohu8.com/highlight/detail?id=2564325557","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2564325557?lang=zh_cn&edition=fundamental","pubTime":"2025-09-04 14:14","pubTimestamp":1756966477,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=ganggu","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["09887","PD","BK4023","LU1169590202.USD","ADC","LU1169589451.USD","BK1161","ADC.AU","BK4231","BK4080","BK7095"],"gpt_icon":0},{"id":"2561474908","title":"阿斯利康第二款ADC药物在国内获批用于乳腺癌","url":"https://stock-news.laohu8.com/highlight/detail?id=2561474908","media":"格隆汇","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2561474908?lang=zh_cn&edition=fundamental","pubTime":"2025-08-22 20:38","pubTimestamp":1755866311,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.gelonghui.com/rss/live/live.xml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_gelonghui","symbols":["LU1829250122.USD","LU2236285917.USD","LU2417539215.USD","BK4568","BK4007","BK7095","BK4588","LU0320765992.SGD","LU2462157665.USD","BK4080","BK4585","BK4225","BK4231","HR","AZN","LU0109394709.USD","BK4203","LU2456880835.USD","LU0889565916.HKD","ADC.AU","ADC"],"gpt_icon":0},{"id":"2561474158","title":"阿斯利康宣布注射用德达博妥单抗（达卓优）正式在国内获批用于治疗既往接受过内分泌治疗且在晚期疾病阶段接受过至少一线化疗的不","url":"https://stock-news.laohu8.com/highlight/detail?id=2561474158","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2561474158?lang=zh_cn&edition=fundamental","pubTime":"2025-08-22 20:38","pubTimestamp":1755866311,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["LU2236285917.USD","BK4568","LU0320765992.SGD","LU0889565916.HKD","AZN","LU2462157665.USD","BK7095","BK4225","ADC","BK4080","BK4588","BK4007","LU2456880835.USD","BK4203","LU2417539215.USD","ADC.AU","LU0109394709.USD","BK4231","BK4585","LU1829250122.USD","HR"],"gpt_icon":0},{"id":"2560128083","title":"研报掘金｜中金：上调药明合联目标价至75港元 中期业绩胜预期且订单增长强劲","url":"https://stock-news.laohu8.com/highlight/detail?id=2560128083","media":"格隆汇","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2560128083?lang=zh_cn&edition=fundamental","pubTime":"2025-08-20 11:40","pubTimestamp":1755661213,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"e0480a0531217974a0c2963e4454991e","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.gelonghui.com/rss/live/live.xml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_gelonghui","symbols":["BK4080","BK4231","02268","159938","ADC.AU","BK1515","BK7095","BK1161","SG9999014674.SGD","BK1141","09939","LU2488822045.USD","ADC","BK1574"],"gpt_icon":0},{"id":"2560151287","title":"德琪医药-B(06996.HK)：ATG-022就治疗胃癌/胃食管结合部腺癌获授予突破性治疗药物认定","url":"https://stock-news.laohu8.com/highlight/detail?id=2560151287","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2560151287?lang=zh_cn&edition=fundamental","pubTime":"2025-08-19 12:23","pubTimestamp":1755577393,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=ganggu","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["CDE","LU1223082196.USD","06996","BK1191","ADC","BK4080","LU1223082519.USD","BK7050","LU1223083913.SGD","BK1574","BK7095","BK1583","ADC.AU","BK4017","BK4231","CDE.AU"],"gpt_icon":0}],"pageSize":20,"totalPage":1,"pageCount":1,"totalSize":7,"code":"91000000","status":"200"}]}}